Solengepras (CVN424): A Novel GPR6 Inhibitor in Clinical Development as an Investigational Therapy for Parkinson’s Disease (P11-5.017)
To describe the novel mechanism of solengepras and provide an overview of clinical trials involving solengepras in Parkinson’s Disease(PD).
Authors
- Kelvin L. Chou (ORCID: https://orcid.org/0000-0002-2597-7315)
- Nicola Brice (ORCID: https://orcid.org/0000-0003-4533-9369)
- Marie Thérèse Charles (ORCID: https://orcid.org/0000-0001-7485-906X)
- Mark Carlton
- Catharina Scholl (ORCID: https://orcid.org/0000-0002-1463-5619)
- Lee A. Dawson
- Sagar A. Vaidya
Institutions
- Michigan Department of Health and Human Services (US)
- University of Michigan (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000210649
- Primary Topic
- Pharmaceutical studies and practices
- Type
- article
- Field-Weighted Citation Impact
- 0.00